Introduction
============

Nasopharyngeal carcinoma (NPC) is distinctly epidemic in Southeast Asia[@B1], with the age -adjusted incidence rate (per 100,000 people per year) among men of approximately 20-50 in Southern China [@B2]. NPC is a special type of head and neck cancer, most of which in China are undifferentiated non-keratinizing carcinoma [@B3]. Due to its anatomic characteristics, biological properties and radiosensitivity, radiation therapy has always been the primary treatment modality for nonmetastatic NPC. With continuously improving radiotherapy equipment and technology, intensity modulated radiotherapy (IMRT) is now the current representative accurate radiotherapy technology. Previous studies have reported the great progress of IMRT in the tumor control and quality of life in NPC [@B4]-[@B7].

IMRT can deliver a heterogeneous dose distribution in different target volumes simultaneously, indicating a dose escalation in locality and a dose reduction in adjacent organs at risk [@B8]. Nevertheless, compared with two-dimensional radiotherapy, the greatest drawback of IMRT is the prolonged delivery time. The prolonged treatments not only decrease efficiency and increase the discomfort and involuntary movements of patients on the couch, which may increase the risk of dose deviation and impair the treatment accuracy, but also will stimulate repair of sublethal damage which is a risk for sparing tumors [@B9]-[@B14].

Volumetric modulated arc therapy (VMAT), a technique first proposed by the Yu\'s group [@B15] and developed based on an investigation from Otto [@B16], can change the dose delivery with various gantry arcs dynamically while the gantry rotates around the patient, due to the capability of continuously modulation of multi-leaf collimator (MLC) positions, dose rate and gantry speed simultaneously [@B17]-[@B19]. Different from IMRT technique with static gantry, VMAT does not require the selection of a finite number of fixed gantry angles and allows greater flexibility because it delivers radiotherapy from all beam orientations. Also, because it can finish the entire treatment in a single 360° rotation of the gantry, it is potentially more time-saving. VMAT has been widely used by the radiotherapy community and introduced for clinical use in different treatment sites.

Several excellent studies have investigated the differences between VMAT-based treatment plans and IMRT-based plans in NPC at both planning and clinical level [@B20]-[@B25]. However, previous reports on the dosimetric comparisons were primarily based on the same set of CT images from the same patient. When exposing a patient to radiation, treatment can only be implemented using one technique. It is therefore necessary to perform a comparison of the two radiotherapy techniques in patients who had underwent actual clinical radiation exposure. Besides, the clinical benefit from faster treatment is not so clear.

Therefore, we conduct this research, using a prospectively matched method, to investigate the differences in both plan quality and peripheral doses of VMAT and IMRT in NPC patients, leading to a more comprehensive evaluation of the treatment techniques. Furthermore, tumor regression rates and long-term clinical outcomes of the two techniques are compared directly.

Materials and methods
=====================

Clinical characteristics of the patients
----------------------------------------

Inclusion criteria: (i) newly diagnosed cases of primary NPC with pathological confirmation; (ii) pathologic type of differentiated non-keratinizing carcinoma or undifferentiated non-keratinizing carcinoma (i.e., WHO type II or type III); (iii) age of 20-80 years old; (iv) male or non-pregnant female; (v) in good general condition, with a Karnofsky Performance Status (KPS) score ≥80; (vi) exhibiting no severe systemic disease or exhibiting complications but expected to complete the radiotherapy; and (vii) no evidence of distant metastasis.

Case grouping
-------------

A prospective patient assignment was performed. Patients receiving treatment with VMAT technique (VMAT group) served as the reference benchmark, and patients receiving treatment with IMRT technique (IMRT group) were selected to match the VMAT group in terms of several variables. The matched patient characteristics included age (the difference ≤5 years), gender, T stage, N stage and chemotherapy. The detailed patient assignment procedures are shown in Figure [1](#F1){ref-type="fig"}. The staging of every patient was performed based on the seventh edition of the American Joint Committee on Cancer (AJCC) in 2009[@B26].

Radiotherapy
------------

### Position

All of the patients were in the supine position, with the connecting line of the third cervical vertebrae and the mandibular angled perpendicular to the bed (the head slightly tilted back) and both hands naturally placed on the sides of the body.

### Immobilization and CT simulation scan

The head and upper neck were fixed using a neck and shoulder thermoplastic mask. CT simulation scan was required for all patients, with the scope from the head to the lower edge of the clavicle and a layer thickness of 3 mm. Plain scanning and enhanced scanning were performed.

### Target volumes and OARs delineation

The CT images for both groups were imported in the Monaco® (Elekta Medical Systems, Sweden) physician workstation, on which the target area and the area of organs at risk (OARs) were delineated. The gross tumor volumes (GTVs) were divided into nasopharyngeal primary gross tumor volume (GTVnx) and neck metastatic lymph node gross tumor volume (GTVnd). The clinical target volumes (CTVs) were divided into the high-risk area (CTV1) and the low-risk area (CTV2) on the basis of tumor invasion. The various planning target volumes (PTVs) were defined from the respective target volumes extending 3 mm margins with 3D expansion, corresponding to PGTVnx, PGTVnd, PTV1 and PTV2. The OARs included the brain stem, spinal cord, temporal lobes, pituitary, optic chiasm, optic nerves, lenses, inner ears, temporomandibular joints, parotid glands, and mandible.

### Dose prescription and optimization

Dose optimization and calculation were performed on the Eclipse treatment planning system (version 10.0 or 11.0, Varian Medical System, USA) or the Monaco treatment planning system (version 3.2, Elekta, Sweden), according to the corresponding radiotherapy machines. Both VMAT and IMRT were generated using a 6 MV X-ray system. Based on the tumor volume and the degree of invasion, a single or double arc design was used in VMAT. A 7- or 9-field design was used for IMRT, with similar optimization conditions. The prescribed doses were as follows: 68-72 Gy to the PGTVnx, 64-68 Gy to the PGTVnd, 60 Gy to the PTV1, and 54-56 Gy to the PTV2, in 30-33 fractions. Radiation was delivered once per day, at 5 fractions per week. For all of the plans, the prescribed dose was required to cover at least 95% of the PTV. Besides, the totally volume that received exceed 110% of the prescribed dose was restrained less than 20% inside every PTV but not allowed in any area outside the PTVs. All efforts were made to prevent the dose received by OARs from exceeding the following RTOG0225 and RTOG0615 dose limits: maximum dose (Dmax) \<45 Gy for the spinal cord; Dmax \<54 Gy for the brain stem, optic nerve and optic chiasm; Dmax \<8 Gy for the lens; Dmax \<70 Gy for temporomandibular joint; Dmean \<46 Gy for inner ear; and the percentage of parotid gland volume receiving 30 Gy (V30) \<50%.

### Evaluations of plans

The quality of radiotherapy plan was evaluated according to the recommendations of the ICRU83 report. It suggests that using Dmax and the minimum dose (Dmin) of PTVs to evaluate the plan\'s quality is not so appropriate. Rather, the near maximum dose (D2) and the near minimum dose (D98) are recommended. So, this study used parameters of median dose (D50), D2, D98, the dose received by 95% of the volume (D95), conformity index (CI) and homogeneity index (HI) to assess the target coverage. The MUs per fraction and average treatment time of the two radiotherapy plans were also considered.

The CI formula[@B27] is as follows: CI=(PTVref/VPTV)×(PTVref/V95%), where PTVref represents the volume of the PTV receiving 95% of the prescribed dose, VPTV represents the PTV volume, and V95% represents the volume covered by the 95% isodose. The closer the CI is to 1, the better the conformity is. The HI formula[@B28] is as follows: HI=(D2-D98)/D50, where D2, D98 and D50 are the doses received by 2%, 98% and 50% of the PTV volume. The closer HI is to 0, the better the homogeneity is. The parameters for comparing vital OARs were Dmax and Dmean.

In the CT images obtained from the patients, all of the outlined target areas were subtracted from the total volume within the outer contour, and all of the resulting volumes were defined as areas of healthy tissue. The volumes of healthy tissue receiving dose of 5 Gy, 10 Gy, 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy and 45Gy were defined as V5, V10, V15, V20, V25, V30, V35, V40 and V45, respectively. The above parameters were analyzed and compared between two plans of techniques.

Chemotherapy
------------

Overall, 89.5% (17/19) patients from each group with stage III or IVA-B disease (T3-T4 or N2-N3) received chemotherapy, including concomitant chemotherapy with or without inductive chemotherapy. Those who rejected to receive chemotherapy were due to personal reasons. Inductive chemotherapy consisted of cisplatin with 5-fluorouracil (PF), cisplatin with docetaxel (TP) or a triplet of cisplatin, 5-fluorouracil and docetaxel (TPF) every 3 weeks for two to three cycles. Concomitant chemotherapy was cisplatin weekly (30-40 mg/m^2^) or on weeks 1, 4 and 7 (80-100 mg/m^2^) of radiotherapy.

Evaluation criteria for the efficacy
------------------------------------

The treatment response and short-term efficacy of the primary tumor and the neck lymph nodes were evaluated by physical examination, electronic nasopharyngeal microscopy and Magnetic Resonance Imaging (MRI) 3 months after the end of the radiotherapy. The efficacy evaluation was based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.0 (RECIST v1.0).

Statistical methods
-------------------

All of the data were analyzed using SPSS 23.0 software. The t-test for two independent samples was used to compare the differences between two groups. Two-sided tests were performed, and differences with p\<0.05 were considered as statistically significance. The short-term efficacy was assessed at the time of three months after the radiotherapy. The follow-up duration was calculated from the first day of therapy to the day of death or last examination. The probabilities of local relapse-free survival (LRFS), regional relapse-free survival (RRFS) and locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), overall survival (OS) were estimated using the Kaplan-Meier method. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit (RDD) public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)), with the approval RDD number as RDDA2017000176.

Results
=======

General patient characteristics
-------------------------------

From June 2013 to August 2015, a total of 80 patients with NPC who received treatment in the Sun Yat-sen University Cancer Center were included in the study. According to the matching procedures described above, the VMAT and IMRT groups each consisted of 40 cases. The general clinical data of the patients are shown in Table [1](#T1){ref-type="table"}.

Comparison of the dose distribution in the PTVs
-----------------------------------------------

All plans met the requirement for the prescribed dose coverage of the target. As shown in Table [2](#T2){ref-type="table"}, there were no significant differences in the volumes of PGTVs between the two groups when considering all groups, the locally early stage (T1-2) subgroups and the locally advanced stage (T3-4) subgroups (p=0.745, 0.199 and 0.201, respectively). D98, D95 or D50 of the PGTVs were similar, while D2 of the VMAT group was significantly lower than that of the IMRT group (p=0.025). Additionally, subgroup analysis found that the significant difference in D2 was primarily in the early stage disease (T1-2) (VMAT vs. IMRT, 7494±109 cGy vs. 7564±92 cGy; p=0.016).

The comparisons of HI and CI between two groups were also shown in Table [2](#T2){ref-type="table"}. The subgroup analysis showed that the difference of HI was primarily in the early stage disease (T1-2) (p=0.001).

Comparison of the dose distribution of sparing OARs and healthy tissue
----------------------------------------------------------------------

The differences in exposure doses of the OARs between the two groups are summarized in Table [3](#T3){ref-type="table"}. The Dmax received by the brainstem, spinal cord, and optic nerve in the VMAT group were slightly higher than those in the IMRT group (p\<0.05). The irradiation received by most other structures was similar between two groups, including the temporal lobe, pituitary, optic chiasm, lens, and parotid gland.

The subgroup analysis showed that, for the spinal cord, Dmax of VMAT plans was higher significantly, no matter in T1-2 patients or in T3-4 patients (p\<0.05). For the brain stem, difference of Dmax was only observed in T1-2 patients.

The irradiation volumes in healthy tissue outside the target areas of the VMAT group were lower than those of the IMRT group, but only V20, V25 and V45 showed statistically significant differences (p\<0.05), as shown in Figure [2](#F2){ref-type="fig"}.

Comparison of the MUs and delivery time
---------------------------------------

The number of MU per fraction resulted to be 698.06±147.07 in VMAT and 1397.01±329.38 in IMRT (p=0.001). IMRT plans showed values of MUs doubled compared to VMAT plans. The average treatment time for VMAT, as measured manually during treatment delivery, was 363 ± 162 s compared to 1160 ± 204 s for IMRT (p=0.042). VMAT plans resulted in a 69% reduction in delivery time consumed.

Comparison of the clinical outcomes
-----------------------------------

The median follow-up period was 29 months (range, 6-48 months). The results of short-term efficacy showed that the nasopharyngeal lesions in 5 cases in each group had not completely subsided, and distant metastasis occurred in 1 case from each group. All 5 cases of nasopharyngeal residual lesions in the VMAT group had completely subsided by more than 6 months after radiotherapy. The residual lesions in 4 cases in the IMRT group had completely subsided by this time point, while 1 case still exhibited residual lesions in the nasopharyngeal examination one year after radiotherapy. There was no significant difference in the tumor regression rates between the two groups.

The 2-year estimated LRFS, RRFS, LRRFS, DMFS, DFS and OS rates were similar between two groups, with the corresponding rates of 100%, 97.4%, 97.4%, 90.0%, 90.0% and 92.4% in VMAT group, and 100%, 100%, 100%, 95.0%, 95.0% and 97.5% in IMRT group, respectively (Figure [3](#F3){ref-type="fig"}). Local failure did not occur in both of this two groups until the end of follow-up.

Discussion
==========

Radiotherapy is the preferred and effective treatment for NPC. The continuous advances in radiotherapy technology have led to significant therapeutic benefits for patients. The results of the clinical application of IMRT showed that it not only significantly improved the local control and long-term survival rates of NPC but also the quality of life of the patients. VMAT technique has been widely accepted in recent years with the biggest advantage of faster treatment time. In addition, it has been confirmed that VMAT has dose distributions comparable to or better than IMRT in the treatment of head and neck tumors and some somatic tumors[@B29]-[@B31].

In previous studies, the comparisons between VMAT and IMRT techniques were based on two sets of plans which were designed on the same target area of the same patient. In actual clinical practice, however, a patient can only receive one plan of treatment. Therefore, prospectively allocating matched patients randomly to either VMAT plan or IMRT plan, as in this study, can better reflect the actual clinical situation. After a scientific and rational allocation, there were no significant differences between the two matched groups in the volume of the gross tumor. Both VMAT and IMRT plans met the clinical requirements of prescribed dose coverage of the PTVs, which is consistent with the findings of Vanetti et al.[@B32] and Johnston et al.[@B33].

The comparison of the dose distribution on the target area showed that the VMAT and IMRT plans did not differ a great deal difference overall. VMAT plan owned a significantly lower D2 and a better HI, but a slightly worse CI, the reason of which was possibly related with a more share out of radiation dose by the healthy tissue when gantry rotating (high V40 and V45). Subgroup analysis showed that the difference in homogeneity between the two groups was primarily in the early stage disease. And it seemed that IMRT was more likely to generate an excessive dose which we usually called \"hot spot\" in the tumor area for the early stage lesion. We considered that it was the intrinsic property of highly conformity of IMRT technique that leading to such steep high-dose gradient at the target edge. Nevertheless, for the locally advanced disease, neither homogeneity nor conformity were seen differences between the two techniques. The reason was that, due to the bulky tumor lesion and the proximity of adjacent vital organs in locally advanced disease, a compromise was made to meet the clinical requirement of radical radiotherapy firstly.

In terms of sparing OARs, IMRT plans protected the brainstem and spinal cord better, which is slightly different from the findings of previous studies. Vanetti et al.[@B32] reported that the dose of VMAT was 37.7% lower than that of IMRT in the brainstem and 8.9% lower in the spinal cord. Similarly, Lee et al.[@B20] demonstrated that the dose received by brain stem with the VMAT plan was lower than with the IMRT plan in locally advanced NPC. For other OARs, such as the mean dose received by parotid gland, VMAT plan could also make a good constraint. The study of Johnston et al.[@B33] also provided that VMAT had a greater advantage in protection of parotid gland. The reason for the different results may be because double-arc VMAT technique and step-and-shoot IMRT technique were used in the above studies. In contrast, in the present study, single arc VMAT technique was applied in 70% (28/40) of patients in the VMAT group, and dynamic sliding window IMRT technique was applied in 90% (36/40) of patients in the IMRT group. The studies of Guckenberger et al.[@B34] and Lee et al.[@B35] have proved that, in terms of dose distribution, double-arc VMAT planning is superior to single-arc planning and that dynamic IMRT is superior to step-and-shoot IMRT.

The exposure volumes of the healthy tissue outside the target area were compared for the two techniques. We found that the exposure volume of healthy tissue in the low-dose area (V5-V35) was smaller for VMAT, especially in the V20-V25 dose range. This finding is consistent with previous reports[@B20],[@B32]. In cases of long-term survival, this advantage may reduce the risk of secondary tumor induced by radiation.

Our study reported that the clinical outcomes, either for the short-term tumor regression rates or for the 2-year survival rates, were highly similar between VMAT and IMRT plans. This result is consistent with the findings reported by Guo et al.[@B23]. Guo et al. also revealed that it was the volume of tumor, not the T-staging, associated with advanced disease, poor prognosis, distant metastasis and local recurrence [@B23]. Reviewed our study, the GTVs between two groups were comparable, which excluded the impact of primary lesion volume on tumor regression. This fact further confirmed the comparable efficacies between the two techniques. Our results also showed that the average MU of the VMAT plan was lower than that of the IMRT plan by approximately 50%, and moreover, VMAT consumed an overwhelming reduction of 69% in treatment time compared with IMRT. In this respect, VMAT can offer an excellent tumor control more efficiency, which will improve comfort and ensure the stability of the patient\'s position. Moreover, faster treatment time of each exposure can increase the number of patients who can undergo treatment. Therefore, VMAT radiotherapy equipment can be used in a more efficient manner, and more patients can receive timely treatment.

Conclusion
==========

In summary, both VMAT and IMRT can meet the clinical requirements for the treatment of NPC. The homogeneity of VMAT in the tumor target area is better, while IMRT can better protect the brain stem and spinal cord in patients with locally early stage disease. The short-term tumor regression rates and 2-year survival rates with the two techniques are comparable. The faster treatment time benefits of VMAT will enable more patients to receive precision radiotherapy.
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![**The trial flow chart is shown.** NPC indicates nasopharyngeal carcinoma; VMAT, volumetric modulated arc therapy; IMRT, intensity modulated radiation therapy; RT, radiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; 2y, two-year; LRFS, local relapse-free survival; RRFS, regional relapse-free survival; LRRFS, locoregional relapse-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival; OS, overall survival.](jcav09p0978g001){#F1}

![**Comparison of the exposure doses and volumes in the healthy tissue.** VMAT indicates volumetric modulated arc therapy; IMRT, intensity modulated radiation therapy. V5, V10, V15, V20, V25, V30, V35, V40 and V45 represents the volumes of healthy tissue receiving 5 Gy, 10 Gy, 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy and 45Gy, respectively. \* represents significant differences (p\<0.05).](jcav09p0978g002){#F2}

![**Kaplan-Meier survival curves of NPC patients treated with VMAT and IMRT.** NPC indicates nasopharyngeal carcinoma; VMAT, volumetric modulated arc therapy; IMRT, intensity modulated radiation therapy.](jcav09p0978g003){#F3}

###### 

Clinical Characteristics of patients with VMAT or IMRT

  Characteristics                            VMAT                    IMRT               *P*                
  ------------------------------------------ ----------------------- ------------------ ------------------ -------
  **Sex, no (%)**                                                                       NS                 
                                             Male                    29 (72.5)          29 (72.5)          
                                             Female                  11 (27.5)          11 (27.5)          
  **Age, years**                                                                        0.725              
                                             Median                  50.5               51.0               
                                             Range                   22.0-65.0          23.0-67.0          
  **T Stage (7^th^ AJCC), no. (%)**                                                     NS                 
                                             T1                      12 (30.0)          13 (32.5)          
                                             T2                      14 (35.0)          13 (32.5)          
                                             T3                      9 (22.5)           9 (22.5)           
                                             T4                      5 (12.5)           5 (12.5)           
  **N Stage (7^th^ AJCC), no. (%)**                                                     NS                 
                                             N0                      17 (42.5)          16 (40.0)          
                                             N1                      13 (32.5)          14 (35.0)          
                                             N2                      9 (22.5)           9 (22.5)           
                                             N3                      1 (2.5)            1 (2.5)            
  **Clinical stage (7^th^ AJCC), no. (%)**                                              NS                 
                                             I                       8 (20.0)           8 (20.0)           
                                             II                      13 (32.5)          13 (32.5)          
                                             III                     13 (32.5)          13 (32.5)          
                                             IVA                     5 (12.5)           5 (12.5)           
                                             IVB                     1 (2.5)            1 (2.5)            
  **Dose for primary site, cGy**                                                                           
                                             Total dose\*            6996 (6789-7029)   7020 (6810-7062)   0.060
                                             Dose/fraction\*         226 (212-234)      227 (212-234)      0.302
  **Treatment time, days**                                                              0.129              
                                             Median                  44                 43                 
                                             Interquartile range     42-45              42-44              
  **Chemotherapy, no. (%)**                                                             NS                 
                                             Induction               1 (2.5)            1 (2.5)            
                                             Concurrent              9 (22.5)           9 (22.5)           
                                             Induction+ concurrent   11 (27.5)          11 (27.5)          
                                             None                    19 (47.5)          19 (47.5)          

Abbreviations: VMAT, volumetric modulated arc therapy; IMRT, intensity modulated radiation therapy; AJCC, American Joint Committee on Cancer; cGy, centigray; NS, nonsignificant.

\* Data are presented as median (range).

###### 

Dosimetric comparison of VMAT and IMRT for the PGTVnxs (![](jcav09p0978i001.jpg))

  Parameters        VMAT          IMRT          *P*
  ----------------- ------------- ------------- -------
  **All (n=80)**                                
  Volume (cm^3^)    37.45±34.72   36.30±27.87   0.745
  D98^\#^ (cGy)     7151±103      7158±89       0.750
  D95^§^ (cGy)      7189±102      7197±90       0.706
  D50^&^ (cGy)      7335±99       7365±97       0.183
  D2^\*^ (cGy)      7509±104      7562±106      0.025
  HI                0.048±0.010   0.056±0.009   0.001
  CI                0.30±0.11     0.35±0.11     0.061
  **T1-2 (n=52)**                               
  Volume (cm^3^)    20.65±15.31   24.62±10.47   0.199
  D98^\#^ (cGy)     7159±122      7169±74       0.705
  D95^§^ (cGy)      7191±122      7208±77       0.550
  D50^&^ (cGy)      7330±118      7368±83       0.186
  D2^\*^ (cGy)      7494±109      7564±92       0.016
  HI                0.045±0.009   0.054±0.009   0.001
  CI                0.29±0.10     0.32±0.11     0.213
  **T3-4 (n=28)**                               
  Volume (cm^3^)    68.64±39.41   58.00±36.61   0.201
  D98^\#^ (cGy)     7137±60       7137±111      0.997
  D95^§^ (cGy)      7186±48       7178±111      0.794
  D50^&^ (cGy)      7346±51       7360±123      0.701
  D2^\*^ (cGy)      7536±90       7559±131      0.600
  HI                0.054±0.013   0.059±0.009   0.250
  CI                0.34±0.12     0.40±0.10     0.129

Abbreviations: PTV, planning target volume; HI, homogeneity index; CI, conformity index; VMAT, volumetric modulated arc therapy; IMRT, intensity modulated radiation therapy; cGy, centigray; T, T stage.

\#: Dose received by 98% of the volume; §: Dose received by 95% of the volume; &: Dose received by 50% of the volume; \*: Dose received by 2% of the volume.

###### 

Dosimetric comparison of VMAT and IMRT for the organs at risk (OARs) (![](jcav09p0978i002.jpg))

  OARs                Index   VMAT (cGy)   IMRT (cGy)   *P*
  ------------------- ------- ------------ ------------ ---------
  All (n=80)                                            
  Brain Stem          Dmax    5879±555     5532±575     0.007
  Spinal Cord         Dmax    4123±327     3766±221     \<0.001
  Temporal Lobe \_L   Dmax    6796±483     6704±548     0.428
  Temporal Lobe \_R   Dmax    6741±462     6812±569     0.541
  Pituitary           Dmax    5872±810     5546±1115    0.139
  Optic Chiasm        Dmax    4319±1682    3925±1886    0.327
  Optic Nerves \_L    Dmax    3550±1867    2545±1918    0.020
  Optic Nerves \_R    Dmax    3668±1901    2707±2031    0.032
  Lens \_L            Dmax    527±247      455±208      0.160
  Lens \_R            Dmax    575±314      470±248      0.101
  Inner ear \_L       Dmean   4437±967     4379±548     0.743
  Inner ear \_R       Dmean   4156±965     4530±692     0.050
  TM Joint \_L        Dmean   4084±771     3848±527     0.115
  TM Joint \_R        Dmean   4193±828     4006±689     0.277
  Mandible \_L        Dmean   4039±495     4050±405     0.916
  Mandible \_R        Dmean   4037±543     4119±427     0.458
  Parotid \_L         Dmean   3747±527     3841±609     0.464
  Parotid \_R         Dmean   3880±648     3861±384     0.873
  T1-2 (n=52)                                           
  Brain Stem          Dmax    5614±371     5322±397     0.008
  Spinal Cord         Dmax    4081±354     3774±228     0.001
  Optic Nerves \_L    Dmax    2738±1675    2134±1689    0.201
  Optic Nerves \_R    Dmax    2887±1730    2185±1685    0.144
  T3-4 (n=28)                                           
  Brain Stem          Dmax    6372±507     5923±659     0.054
  Spinal Cord         Dmax    4201±263     3750±217     \<0.001
  Optic Nerves \_L    Dmax    5057±1138    3309±2141    0.014
  Optic Nerves \_R    Dmax    5117±1269    3678±2315    0.055

Abbreviations: VMAT, volumetric modulated arc therapy; IMRT, intensity modulated radiation therapy; OAR, organ at risk; cGy, centigray; T, T stage; L, left; R, right; Dmax, the maximun dose; Dmean, the mean dose.
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